{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:51:54Z","timestamp":1791193914258,"version":"4.1.0"},"reference-count":26,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) progresses when nutrient excess, insulin resistance, adipose dysfunction, and hepatocellular stress overwhelm hepatic adaptation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve weight, glycemic control, and steatohepatitis, and semaglutide has demonstrated histological improvement in metabolic dysfunction-associated steatohepatitis (MASH). In parallel, the transcriptional coactivator with PDZ-binding motif (TAZ; WWTR1) has emerged as a nutrient-, cholesterol-, and mechanics-responsive regulator linking stressed hepatocytes to inflammation and fibrogenesis through Hippo-YAP\/TAZ signaling and Indian hedgehog. This narrative review integrates incretin physiology with cell-specific TAZ biology across the gut\u2013brain\u2013axis, adipose tissue, pancreatic islets, liver sinusoidal endothelial cells, hepatocytes, immune cells, and hepatic stellate cells. Recent evidence that semaglutide can signal through intrahepatic sinusoidal endothelial GLP-1 receptors provides a weight-loss-independent route to reduced hepatic inflammation and fibrosis; however, it does not establish that TAZ is a downstream mediator. The evidence therefore supports a multilevel convergence model in which GLP-1RAs lower metabolic and inflammatory inputs that favor TAZ activation, while direct GLP-1RA-to-TAZ signaling remains a testable hypothesis. Receptor-validated, cell-specific, weight-controlled, and longitudinal human studies are needed to distinguish mediation from parallel response and to determine whether TAZ-pathway biomarkers can guide mechanism-based therapy.<\/jats:p>","DOI":"10.3390\/cells15191813","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:57:18Z","timestamp":1791190638000},"page":"1813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential Physiological Convergence Between GLP-1 Receptor Signaling and Hepatocyte TAZ in Metabolic Liver Disease: From Metabolic Homeostasis to Fibrotic Remodeling"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5914-8524","authenticated-orcid":false,"given":"Mohammed F.","family":"Gholam","sequence":"first","affiliation":[{"name":"King Abdullah International Medical Research Center, Jeddah 21423, Saudi Arabia"},{"name":"Department of Basic Medical Sciences, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah 21423, Saudi Arabia"},{"name":"Ministry of the National Guard\u2013Health Affairs, Jeddah 21423, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: From basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction\u2013Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_7","first-page":"1","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"Lima","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.cmet.2026.03.011","article-title":"The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors","volume":"38","author":"Riobello","year":"2026","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nature10137","article-title":"Role of YAP\/TAZ in mechanotransduction","volume":"474","author":"Dupont","year":"2011","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s12272-024-01501-5","article-title":"Interplay between YAP\/TAZ and metabolic dysfunction-associated steatotic liver disease progression","volume":"47","author":"Lee","year":"2024","journal-title":"Arch. Pharmacal Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/cas.15352","article-title":"Physiological and pathological roles of the Hippo-YAP\/TAZ signaling pathway in liver formation, homeostasis, and tumorigenesis","volume":"113","author":"Nishina","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.cmet.2016.09.016","article-title":"Hepatocyte TAZ\/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis","volume":"24","author":"Wang","year":"2016","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1152\/physrev.00013.2007","article-title":"Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver","volume":"88","author":"Friedman","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Haak, A.J., Kostallari, E., Sicard, D., Ligresti, G., Choi, K.M., Caporarello, N., Jones, D.L., Tan, Q., Meridew, J., and Espinosa, A.M.D. (2019). Selective YAP\/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci. Transl. Med., 11.","DOI":"10.1126\/scitranslmed.aau6296"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling Pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Niu, S., Chen, S., Chen, X., Ren, Q., Yue, L., Pan, X., Zhao, H., Li, Z., and Chen, X. (2022). Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1046130"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2021.02.026","article-title":"Myofibroblast YAP\/TAZ is dispensable for liver fibrosis in mice","volume":"75","author":"Xu","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/hep.30928","article-title":"Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis","volume":"71","author":"Mooring","year":"2019","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101165","DOI":"10.1016\/j.omtm.2023.101165","article-title":"Hepatocyte-targeted siTAZ therapy lowers liver fibrosis in NASH diet-fed chimeric mice with hepatocyte-humanized livers","volume":"31","author":"Wang","year":"2023","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/hep4.1405","article-title":"A Therapeutic Silencing RNA Targeting Hepatocyte TAZ Prevents and Reverses Fibrosis in Nonalcoholic Steatohepatitis in Mice","volume":"3","author":"Wang","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100716","DOI":"10.1016\/j.jhepr.2023.100716","article-title":"Circulating indian hedgehog is a marker of the hepatocyte-TAZ pathway in experimental NASH and is elevated in humans with NASH","volume":"5","author":"Moore","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in Participants With Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:00:25Z","timestamp":1791190825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":26,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cells15191813"],"URL":"https:\/\/doi.org\/10.3390\/cells15191813","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]}}}